STEMCELL Technologies Announces Acquisition of Propagenix Inc.

STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Propagenix Inc.—a Maryland-based biotechnology company focused on developing technologies to enable new approaches in regenerative medicine. Founded in 2014, Propagenix has developed and commercialized unique technologies, including its patented EpiX™ technology. In 2017, STEMCELL licensed the rights to EpiX™ for research use applications. This technology has the potential to address clinical needs in replacing a patient’s own damaged barrier tissues, like skin and intestinal tissue, with engineered tissue solutions. The current acquisition now enables STEMCELL to develop products based on EpiX™ technology for clinical applications.

Read the full article: STEMCELL Technologies Announces Acquisition of Propagenix Inc. //

Source: https://www.businesswire.com/news/home/20240119648511/en/STEMCELL-Technologies-Announces-Acquisition-of-Propagenix-Inc.

Leave a Comment

Your email address will not be published.

Scroll to Top